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Abstract
Recent genome-wide association studies report that the SNP rs8099917, located 8.9 kb upstream of the start codon of
IL28B, is associated with both disease chronicity and therapeutic response to pegIFN-a and RBV in patients infected with
genotype 1 HCV. To determine the effect of rs8099917 variation on the response of HCV to therapy, we genotyped this
variant in a cohort of 160 HCV/HIV-1 coinfected patients in our clinic unit who received combined peg-IFN-a/RBV therapy.
The rs8099917 T/G or G/G genotypes were observed in 56 patients (35%). Treatment failure occurred in 80% of G-allele
carriers versus 48% of non-carriers (P,0.0001). This result reveals that the G allele was strongly associated with treatment
failure in this patient cohort. Importantly, a highly significant association was found between the G-allele and response to
therapy in HCV genotype 1-infected patients (P,0.0001) but not in HCV genotype 3-infected patients. Multivariate analysis
(odds ratio; 95% confidence interval; P value) indicated that the rs8099917 TT genotype was a strong predictor of treatment
success (5.83; 1.26–26.92; P=0.021), independent of baseline plasma HCV-RNA load less than 500 000 IU/ml (4.85; 1.18–
19.95; P=0.025) and absence of advanced liver fibrosis (5.24; 1.20–22.91; P=0.025). These results reveal the high prevalence
of the rs8099917 G allele in HCV/HIV-1 coinfected patients as well as its strong association with treatment failure in HCV
genotype 1-infected patients. rs8099917 SNP genotyping may be a valid pre-treatment predictor of which patients are likely
to respond to treatment in this group of difficult-to-treat HCV/HIV-infected patients.
Citation: Aparicio E, Parera M, Franco S, Pe ´rez-Alvarez N, Tural C, et al. (2010) IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-a and
Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients. PLoS ONE 5(10): e13771. doi:10.1371/journal.pone.0013771
Editor: Esper Georges Kallas, University of Sao Paulo, Brazil
Received June 22, 2010; Accepted October 6, 2010; Published October 29, 2010
Copyright:  2010 Aparicio et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Spanish Ministerio de Ciencia e Innovacion, Fondo de Investigaciones Sanitarias project PI07/0098 and through "Red
Tematica de Investigacion Cooperativa en SIDA" Grant RD06/0006. The funders had no role in study design, data collection and analysis,decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mmartinez@irsicaixa.es
Introduction
The hepatitis C virus (HCV), a positive-stranded RNA virus, is the
causal agent of chronicliver infection afflicting more than 170 million
people worldwide [1]. HCV infection is usually persistent, with 70–
80% of patients becoming chronic carriers. After an asymptomatic
period that often lasts for years, many patients develop chronic liver
disease, including cirrhosis and hepatocellular carcinoma [2].
The standard of care for patients with chronic hepatitis C is
pegylated interferon alpha (peg-IFN-a) in combination with
ribavirin (RBV) [3]. A positive response to treatment is defined
as a sustained virological response (SVR; a negative hepatitis C
PCR test 6 months after cessation of therapy). The SVR rate for
individuals infected with HCV genotypes 1 or 4 ranges between 40
and 50% and requires 12 months of therapy. Patients infected with
HCV genotypes 2 or 3 typically achieve SVRs of nearly 75% after
only 6 months of therapy [4,5,6,7]. HCV genotype is the most
important predictive factor for the treatment response of patients
with chronic hepatitis C; however, host factors such as age, sex,
race, liver fibrosis, and obesity have also been associated with peg-
IFN-a/RBV therapy outcome [8,9].
ChronicHCVinfection in human immunodeficiencyvirus type
1- (HIV-1-) positive patients is a frequent and emerging health
problem. HCV and HIV-1 are both transmitted by blood and
blood products. Coinfection is therefore common in people with
high exposure to blood. Hepatitis C is found in 60 to 90% of HIV-
1-positive hemophiliacs and in 50 to 70% of HIV-1-positive
intravenous drug users [10]. Although sexual transmission of
HCV is rare, small epidemics of acute hepatitis C have been
reported recently in homosexual men. In our clinic unit, nearly
50% of the HIV-1 patients are coinfected with HCV [11]. In the
highly active antiretroviral therapy (HAART) era, HCV/HIV-1
coinfection increases the risk of hospitalization and death
compared with HIV-1 infection alone [12]. Importantly, standard
therapy with peg-IFN-a/RBV elicits significantly lower rates of
SVR in HCV/HIV-1 coinfected patients than in HCV mono-
infected individuals. Among patients infected with HCV geno-
types 1 or 4, the SVR rate is only about 30%. The corresponding
rate among patients infected with HCV genotype 2 or 3 is closer
to 60% [13,14]. These results illustrate the difficulties in
successfully treating HCV infection in HCV/HIV-1 coinfected
patients.
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ations of several single nucleotide polymorphism (SNP) in the
IL28B gene on chromosome 19, which encodes type III IFN-l,
with the response to HCV peg-IFN-a/RBV-based therapy
[15,16,17,18]. Interestingly, the rs8099917 SNP was the only
SNP in these four studies that was strongly associated with
response to therapy, but the studies did not specifically investigate
the association between IL28B variation and response to peg-IFN-
a/RBV-based therapy in HCV/HIV-1 coinfected patients.
Recently, the rs12979860 SNP, also located near the IL28B gene,
has been associated with HCV treatment response in HIV-1-
infected patients with chronic hepatitis C due to genotypes 1 or 4
[19,20]. To directly address the role of the rs8099917 SNP in
HCV treatment response in HCV/HIV-1 coinfected patients, we
genotyped 160 individuals from our clinic unit who were treated
with peg-IFN-a/RBV combination therapy.
Results
rs8099917 SNP prevalence
Of the 160 patients in the study, 86 (54%) were chronically
infected with HCV genotypes 1, 46 (29%) with HCV genotype 3,
and 28 (17%) with HCV genotype 4 (Table 1). To genotype the
rs8099917 SNP, we developed a direct sequencing PCR-based
protocol.Genotypingrevealed a highprevalence of G alleles (TG or
GG) in our study cohort (n=56, 35%) (Table 2). rs8099917
genotypes were in the Hardy-Weinberg equilibrium (P=0.118). No
significant associations were found between the rs8099917 SNP
genotype and patient sex, age, CD4+ T cell count, HBV infection,
liver enzyme levels, liver fibrosis, or HCV RNA viral load (data not
shown). The proportion of the rs8099917 TT, TG, and GG
genotypes were 60%, 35%, and 5% among HCV genotype 1
patients; 78%, 15%, and 7% among genotype 3 patients; and 57%,
29%, and 14% among genotype 4 patients. Genotypes 1 and 4
showed similar proportion of G alleles, 40% and 43%, respectively.
Interestingly, there was a significant difference between the
prevalence of G alleles in HCV genotype 3-infected patients,
22%, and the prevalence in patients infected with HCVgenotypes 1
or 4 (P,0.05, Chi-square test). The lower proportion of the G allele
in genotype 3-infected patients suggested that G carriers may be less
prone to be chronically infected by genotype 3 viruses or,
alternatively, that the rs8099917 homozygous TT genotype is not
associated with spontaneous clearance of HCV genotype 3.
rs8099917 SNP and treatment response
The clinical characteristics and HCV treatment responses of the
160 HCV/HIV-1 coinfected patients included in the study are
summarized in Table 1. Most patients were on antiretroviral
therapy (159, 99.5%), and most patients had controlled HIV-1
replication (130, 81%). Sixty-seven patients (42%) responded
successfully to HCV treatment (i.e. achieved SVR). The
proportion of patients infected with HCV genotype 3 who
achieved SVR (63%) was significantly higher than in patients
infected with HCV genotypes 1 or 4 (34% and 32%, respectively)
(P,0.05, Chi-square test). A significantly higher HCV RNA viral
load was observed in patients who failed treatment (P,0.05,
unpaired t test). Likewise, severe fibrosis was significantly
associated with treatment failure (P,0.05, Chi-square test)
(Table 1). These three clinical parameters, HCV genotype,
HCV RNA viral load, and severe fibrosis, are known to be
associated with treatment response. We found no significant
differences in our study cohort between those who achieved SVR
and those who did not with respect to sex, age, HIV-1 viral load,
liver enzymes, or CD4+ T cell count (Table 1).
Table 1. Clinical Characteristics of patients with chronic HIV-1 and HCV co-infection and treated with peg-IFN-a/RBV therapy.
Treatment Success Treatment Failure P
Patients, n (%) 67 (42%) 93 (58%) -
Age (mean 6 SEM) 48.4260.6773 47.2160.6283 ns
Gender, n (%) ns
Female 24 (45%) 29 (55%)
Male 43 (40%) 64 (60%)
CD4+ (cell counts/mL) (mean 6 SEM) 597.9627.82 584.6631.85 ns
HCV genotype n (%) ,0.005
1 29 (34%) 57 (66%)
3 29 (63%) 17 (37%)
4 9 (32%) 19 (68%)
Fibrosis stage n (%) ,0.05
0–1 12 (36%) 21 (64%)
2 3 (18%) 14 (82%)
3 1 (11%) 8 (89%)
4 2 (9%) 21 (91%)
ALT (U/L) (mean 6 SEM) 90.84610.90 85.5465.039 ns
AST (U/L) (mean 6 SEM) 60.3166.522 62.3563.248 ns
HCV RNA (IU/mL) (mean 6 SEM) 5.80860.097 6.03660.050 ,0.05
Undetectable HIV-1 RNA, n (%) 55 (82%) 75 (81%) ns
Age, Mann-Whitney U test; Gender, Chi-square test; CD4+T cell count, Mann-Whitney U test; HCV genotype Chi-square test; Fibrosis stage, Chi-square test between F0-2
and F3-4, fibrosis data was missing in 78 patients; ALT and AST, Mann-Whitney U test; HCV RNA, unpaired T test; Undetectable HIV-1, Chi-square test.
doi:10.1371/journal.pone.0013771.t001
IL28B pegIFN-a/RVB HCV/HIV-1
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peg-IFN-a/RBV treatment response. The proportions of
rs8099917 TT, TG, and GG genotypes were 51.5%, 41.0%,
and 7.5% among patients with treatment failure, versus 83.5%,
10.5% and 6% among those with SVR. Overall, allele G carriers
had a significantly higher risk of treatment failure than patients
carrying the TT genotype (P,0.0001, Chi-square test). This
suggests that this rs8099917 SNP may predict treatment failure
before peg-IFN-a/RBV therapy. When the data was stratified by
HCV genotype, we found that of patients infected with HCV
genotype 1, 91% of the rs8099917 G allele carriers had treatment
failure (Fig. 1). Among patients infected with HCV genotype 1, the
association between the rs8099917 G allele and treatment failure
was highly significant (P,0.0001, Chi-square test) (Table 2).
Similarly, of patients infected with HCV genotype 4, 83% of the
rs8099917 G allele carriers failed treatment (Fig. 1 and Table 2).
The sample size of patients infected with HCV genotype 4 was
small (n=28), limiting our ability to detect a significant association
between the G allele and treatment failure. In contrast to patients
infected with HCV genotypes 1 and 4, HCV genotype 3-infected
patients that failed therapy had a similar proportion of TT and
TG/GG genotypes (36% and 40%, respectively) (Fig. 1). Thus for
patients infected with HCV genotype 3, there was no significant
association between rs8099917 SNP genotype and treatment
failure (Table 2).
Next, factors associated with treatment failure as HCV
genotype (P,0.005), fibrosis stage (P,0.05), higher pretreatment
HCV RNA viral load (P,0.05) and rs8099917 SNP genotype
(P,0.0001) (Table 1) were subjected to univariate and multivar-
iate logistic regression analysis (odds ratio; 95% confidence
interval; P value). In the univariate analyses, rs8099917 SNP
genotype TT (4.73; 2.19–10.20; P=0.00006), baseline HCV-
RNA viral load less than 500 000 IU/ml (3.10; 1.44–6.66;
P=0.003), absence of severe liver fibrosis (stages F0–F2) (4.14;
1.06–16.04; P=0.036) and HCV genotype 3 (3.20; 1.58–6.49;
P=0.001) were significantly associated with treatment success.
When a multivariate model was built with the previous factors, the
rs8099917 TT genotype remained a strong predictor of treatment
success (5.83; 1.26–26.92; P=0.021), independently of baseline
plasma HCV-RNA load less than 500 000 IU/ml (4.85; 1.18–
19.95; P=0.025) and fibrosis stages F0–F2 (5.24; 1.20–22.91;
P=0.025).
Discussion
HIV-1 accelerates the course of HCV-associated liver disease.
SVR after peg-IFN-a/RBV therapy in patients coinfected with
HCV/HIV-1 reduces liver-related complications and mortality
[22]. However, side effect rates for anti-HCV therapy in HIV-1
coinfected patients are very high, and premature treatment
Table 2. Association of rs8099917 SNP with response to peg-IFNa/RBV treatment.
Treatment Success (SVR) n = 67 (42%) Treatment Failure n = 93 (58%)
HCV genotype TT TG or GG TT TG or GG P value
1
n=86 (54%)
26 (90%) 3 (10%) 26 (46%) 31 (54%) ,0.0001
3
n=46 (29%)
23 (79%) 6 (21%) 13 (76%) 4 (24%) ns
4
n=28 (17%)
7 (78%) 2 (22%) 9 (47%) 10 (53%) ns
To calculate P values (Chi-square test), patients were stratified in two groups according to host polymorphism (host rs8099917 G allele carriers (TG and GG) versus
noncarriers (TT). SVR, sustained virologic response; ns, not significant, to calculate.
doi:10.1371/journal.pone.0013771.t002
Figure 1. Rate of treatment failure according to rs8099917 SNP genotype in patients with hepatitis C virus (HCV) genotype 1, 3, and
4. P values correspond to Chi-square test.
doi:10.1371/journal.pone.0013771.g001
IL28B pegIFN-a/RVB HCV/HIV-1
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and 30%. Therefore, there is a need to improve treatment
strategies in this specific group of coinfected patients in order to
minimize side effects and treatment discontinuations and to
maximize treatment success. Therapy is particularly recommend-
ed for coinfected patients with a high likelihood of achieving a
SVR, i.e. patients infected with HCV genotype 2 or 3 and those
infected with genotype 1 if the viral load is low (400 000–500
000 IU/mL) [23]. Insulin resistance and liver fibrosis tests are also
recommended for patients with a low likelihood of achieving SVR.
The findings presented here confirm that HCV genotype 1
patients carrying an rs8099917 G allele have a low probability of
treatment success; therefore, rs8099917 genotyping seems to be a
valid pre-treatment approach for maximizing treatment success
and minimizing HCV therapy-related toxicity. Coinfected patients
with HCV genotype 4 may also benefit from rs8099917
genotyping. HCV genotype 4-infected patients carrying
rs8099917 G alleles had similar rates of treatment failure as
HCV genotype 1-infected patients. Nevertheless, the small
number of HCV genotype 4-infected patients in our study
prevented us from drawing conclusions about the predictive value
of rs8099917 genotyping in this group of patients. Overall, our
results are in agreement with those reported by Rallon et al. and
Pineda et al. [19,20], which have demonstrated a significant
influence of the rs12979860 SNP, that is in linkage disequilibrium
with rs8099917 [18], on the treatment response of HIV-1 patients
coinfected with HCV genotypes 1 and 4. In the 160 patients of our
study cohort, the rs12979860 SNP genotype was also highly
associated with treatment success (P,0.0001, Chi-square test)
(4.16; 2.2–8.21; P=0.00003) (manuscript in preparation). How-
ever, it remains to be elucidated which of these two IL28B
associated SNPs are more powerful to predict treatment success.
Similar to findings for HCV-monoinfected patients [18], the
rate of treatment failure in patients infected with HCV genotype 3
was not affected by rs8099917 genotype, suggesting that the
predictive value of genotyping this SNP is limited to patients
infected with HCV genotypes that have low rates of treatment
success. Genetic variation in IL28B and spontaneous clearance of
HCV has also been described [18,24]. In particular, the rs8099917
G allele increases the risk of progression to chronic HCV infection
in both HCV-monoinfected and HCV/HIV-1 coinfected patients
[18]. We found a significantly lower proportion of rs8099917 G
alleles, 22%, in genotype 3-infected patients than would be
expected given the prevalence of this allele (40% and 42%, in
HCV genotype 1- and 4-infected patients, respectively). The
prevalence of rs8099917 G alleles in HCV genotype 3-infected
patients in our study cohort was within the ranges reported in an
unrelated cohort of Swiss Caucasians (17%) [25] and in the
Caucasian cohort of the Human Haplotype Map project
(HapMap, www.hapmap.org) (15–19%); this suggests that the
rs8099917 G allele may not affecting the rate of chronicity of
HCV genotype 3. In contrast, the high prevalence of the
rs8099917 G allele in HCV genotype 1- or 4-infected patients
shows that the rs8099917 TT genotype may have a protective
effect in terms of preventing the persistence of these two HCV
genotypes. Since the rs8099917 G allele has been correlated with
lower expression levels of IL28 genes [17], the different
frequencies of the rs8099917 G allele in patients infected with
different HCV genotypes may indicate that the innate immune
system interacts differently with the different HCV genotypes.
However, the viral factors involved in this interaction remain
unknown. The IL28B, IL28A, and IL29 genes are closely related
cytokine genes in chromosomal region 19q13 that encode proteins
known as type III IFNs (IFN-ls) [26]. IFN-l has been proposed as
a possible treatment for hepatitis C [27,28]. A phase 1b study
involving 4 weeks of peg-IFN-l plus RBV given to patients with
chronic HCV infection showed that this combination had antiviral
activity [27]. A comparison of the efficacy of IFN-l against non-1
HCV genotypes may provide some clues about the interaction of
this virus with the innate immune system.
An important question that remains to be answered is whether
the rs8099917 genotype has higher treatment predictive value in
HCV/HIV-1 coinfected patients than in HCV monoinfected
individuals. Previous studies with HCV genotype 1-monoinfected
patients found that the proportion of rs8099917 G allele carriers
associated with treatment failure ranges from 50% to 87%
[16,17,18]. In our cohort of patients coinfected with HIV-1 and
HCV genotype 1, 88% of the rs8099917 G allele carriers failed
therapy with peg-IFN-a/RBV. This percentage is within the high
range of previous studies and suggests that IL28B genotyping may
have a higher predictive value in coinfected patients. Further
studies of cohorts with different ethnic profiles and treatment
regimes will be necessary to determine whether there are
differences between mono- and coinfected patients in regard to
the predictive value of IL28B genotyping.
The recent development of compounds that directly inhibit
HCV replication through interaction with viral proteins will
increase the options for treating HCV infection. These com-
pounds, which are now in phase 1, 2, and 3 trials, include reagents
that target the HCV nonstructural (NS) 3 protease, the NS5A
protein, and the RNA-dependent RNA-polymerase NS5B [29].
Data from phase 2 studies show that SVR rates improve
significantly in patients receiving triple therapy consisting of an
NS3 protease plus peg-IFN-a/RBV [30]. However, triple therapy
has not been effective in all patients infected with HCV genotype 1
because of side effects, non-responsiveness to peg-IFN-a or RBV,
or development of NS3 protease resistance. The rate of triple
therapy treatment failure may be higher in HCV/HIV-1
coinfected patients. Most of the coinfected patients carrying
IL28B risk alleles treated with this triple therapy may respond only
to the NS3 protease inhibitor. Monotherapy with specific viral
inhibitors poses a higher risk of selection of resistant variants and
treatment failure [31]. Taken together, these results strongly
suggest that more than one specific HCV inhibitor will be needed




A total of 160 HCV/HIV-1 coinfected patients from our HIV
clinic unit who had a standard course of treatment with peg-IFN-a/
RBV with known virological response status at 24 weeks post-
treatment were included in this study. Patient characteristics are
shown in Table 1. Treatment success (i.e. achieved SVR) was
defined as undetectable plasma HCV RNA using a sensitive RT-
PCR assay 24 weeks post-treatment cessation. HCV genotype, a
marker for hepatitis B virus (HBV) infection, HCV and HIV-1 viral
load, CD4+ T cell count, and liver enzymes levels were determined
using standard procedures. Severe fibrosis was considered in
patients with a METAVIR score $F3. Written informed consent
was obtained from each patient who participated in the study.
Likewise, ethics approval was obtained from our Institutional
Review Board (Hospital Universitari Germans Trias i Pujol).
DNA collection and extraction
Blood was collected into EDTA tubes following standard
procedures. Genomic DNA was extracted from peripheral blood
IL28B pegIFN-a/RVB HCV/HIV-1
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Extraction Protocol (EPICENTRE Biotechnologies). Briefly,
2610
6 cells were resuspended in 0.5 mL of QuickExtract Solution,
incubated at 65uC for 10 min, incubated at 98uC for 2 min, and
then stored at 270uC.
rs8099917 SNP genotyping
SNP genotyping was performed by PCR amplification and
direct PCR sequencing. The oligonucleotides used for PCR were
rs8099917–128 (59-GTGCATATGTTTTCTGAC-39, sense) and
rs8099917-556 (59-GAGGCCCCTCACCCATGC-39, antisense).
The PCR amplification mixture contained 5 mL of PBMC
genomic DNA solution, 10 pmol of each oligonucleotide,
200 mM deoxyribonucleoside triphosphates (dNTPs), 2 mM
MgSO4, 1x high-fidelity PCR buffer (Invitrogen), and 0.25 U
Platinum Taq DNA polymerase (Invitrogen) in a total reaction
volume of 50 mL. Cycling parameters were one cycle of
denaturation at 94uC for 2 min, 40 cycles of denaturation at
95uC for 30 s, annealing at 55uC for 30 s, and extension at 68uC
for 30 s. Extension was followed by a 7-min incubation at 68uC.
The resulting 430-nt PCR product was sequenced using two
flanking PCR oligonucleotides, termed rs8099917–128 and
rs8099917–556, with the Big Dye v3.1 kit and the 3100 DNA
sequencing system (Applied Biosystems) as described previously
[21]. Sequence alignment and editing was performed with the
Sequencer version 4.1 (GeneCodes) software program. Hardy-
Weinberg equilibrium was calculated using the Hardy-Weinberg
Calculator software as implemented in http://www.tufts.edu.
Statistical analysis
The association between the rs8099917 SNP and the response
to peg-IFN-a/RBV treatment was assessed by a two-sided Chi-
square test. The Mann-Whitney U test, unpaired t test, and two-
sided Chi-square tests used to analyze baseline covariates were
performed using GraphPad Prism version 4.00 for Windows (San
Diego, CA, USA). Univariate and multivariate logistic regression
analyses were used to determine the predictors of treatment
success. We calculated the odds ratios and 95% confidence
intervals. P values less than 0.05 were considered significant.
Regression analyses were performed using the STATISTICA
software version 9.1 (StatSoft Inc., Tulsa, OK, USA).
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